Welcome to our dedicated page for Hookipa Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on Hookipa Pharma stock.
HOOKIPA Pharma Inc. reports asset-sale, governance, clinical and regulatory, and corporate-status developments tied to its history as a clinical-stage biopharmaceutical company developing immunotherapeutics for cancer and serious infectious diseases. Its disclosed programs included arenavirus-platform cancer vaccine assets such as HB-200 (eseba-vec) and HB-700, as well as HB-400 for hepatitis B virus and HB-500 for HIV.
Company updates have covered completed sales of oncology, HBV, and HIV program assets, collaboration-related activity, board and stockholder matters, operating and financial results, and the voluntary delisting and deregistration process for HOOKIPA common stock.
HOOKIPA Pharma has entered a collaboration with Roche to advance its HB-700 program targeting KRAS-mutated cancers, receiving $25 million upfront and potential milestone payments totaling approximately $930 million. This partnership marks HOOKIPA's first oncology licensing collaboration, where they will lead early research and clinical development for HB-700. Roche may expand the collaboration with an additional product candidate, enhancing the commercial potential of HOOKIPA's proprietary arenavirus platform.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced participation in two major investor conferences: the Morgan Stanley Global Healthcare Conference and the H.C. Wainwright Global Investment Conference, both taking place from September 12-14, 2022 in New York.
The Fireside Chat is scheduled for September 13 at 12:55 PM ET, and can be accessed via HOOKIPA’s website, with archived replays available for 30 days post-event. HOOKIPA focuses on innovative immunotherapies leveraging its proprietary arenavirus platform to tackle diseases, including cancers and viral infections like HBV and HIV.
HOOKIPA Pharma reported promising advancements in its cancer treatments, specifically HB-200 and HB-300. The Phase 1 data for HB-200 in head and neck cancer met all endpoints, leading to a Phase 2 study. Additionally, the FDA accepted the Investigational New Drug Application for HB-300, targeting metastatic castration-resistant prostate cancer. Financially, HOOKIPA's cash position improved significantly, reaching $118.9 million, although revenue fell to $2.7 million from $5.4 million year-over-year, attributed to lower collaboration reimbursements. The net loss decreased slightly to $16.4 million.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) will release its second quarter 2022 financial results and company update on August 11, 2022, prior to market opening. The company, focused on immunotherapies using its proprietary arenavirus platform, aims to mobilize targeted T cells to combat serious diseases. Its pipeline includes investigational therapies for HPV16+ cancers, prostate cancer, KRAS-mutated cancers, and efforts to develop functional cures for HBV and HIV in collaboration with Gilead. No conference call is scheduled for this earnings release.
HOOKIPA Pharma has received FDA acceptance for its IND application for HB-300, a novel immunotherapy targeting metastatic castration-resistant prostate cancer, marking a significant advancement in its oncology pipeline. The Drug Master File (DMF) has also been accepted, facilitating faster clinical development. HB-300 utilizes a dual arenaviral approach to stimulate immune responses against prostate cancer antigens PAP and PSA, with potential expansions to include PSMA. This development is crucial as treatment options are limited for this aggressive cancer form, affecting survival rates.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced key leadership changes effective July 1, 2022, as it advances its clinical development. Igor Matushansky will step down as CMO but will remain as Chair of the Scientific Advisory Board. Katia Schlienger has been promoted to Executive Vice President, Clinical Development, bringing significant experience in oncology therapeutics. Roman Necina becomes Chief Development Officer, integrating project management and operational excellence to enhance pipeline efficiency. The leadership shift aims to strengthen HOOKIPA's capabilities in immunotherapy.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) will participate in investor meetings at the JMP Securities Life Sciences Conference on June 15-16, 2022, in New York City. The company focuses on developing immunotherapeutics based on its proprietary arenavirus platform, which aims to enhance T cell responses against serious diseases. HOOKIPA's pipeline includes therapies targeting HPV16+ cancers, prostate cancer, and KRAS-mutated cancers. Additionally, it seeks to develop functional cures for HBV and HIV in collaboration with Gilead.
HOOKIPA Pharma has reported positive Phase 1 results for its HB-200 program targeting advanced HPV16+ head and neck cancer. The new alternating 2-vector therapy (HB-202/HB-201) demonstrated superior immune and tumor responses compared to the single-vector (HB-201), achieving an 80% disease control rate. Moving forward, HOOKIPA plans to advance to Phase 2 trials, which will explore the new therapy in conjunction with pembrolizumab and also as a standalone treatment in a post-standard care setting. These findings reflect HOOKIPA's commitment to innovative immunotherapy solutions in oncology.
HOOKIPA Pharma presented promising preclinical data on its arenaviral therapeutic vaccines for HIV at the Keystone Symposium. The findings show that an alternating 2-vector therapy resulted in a significantly stronger immune response compared to single-vector therapy, leading to a substantial reduction in viral load. Conducted in collaboration with Gilead Sciences, this research utilized a simian immunodeficiency virus model to assess immune response. HOOKIPA aims to advance this therapy through a Phase 1b clinical trial, supported by Gilead's funding. These investigational compounds have not been approved for use.
HOOKIPA Pharma announced positive Phase 1 trial results for its HB-200 program targeting HPV16+ head and neck cancers. The data showed that both single-vector HB-201 and the 2-vector HB-202/HB-201 therapies were generally well tolerated and induced tumor-specific T cells, demonstrating anti-tumor activity in patients who had undergone extensive prior treatment. The company plans to present these findings at the ASCO Annual Meeting in June 2022, including the recommended Phase 2 dose for HB-202/HB-201.